argenx SE Price (ARGX.BR)

Stock Price

Low: Year Low
High: Year High

Market Cap

Fetching Data...

Enterprise Value

Fetching Data...

Fetching Data...

Shares Outstanding

57,169,253

(5.1265)%

Community Sentiment 0 votes
↑ 0% ↓ 0%

Description

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. Th... Read More

Sector: Healthcare

  • Previous Close Fetching Data...
  • Range $322.5-658
  • Market Cap 34.33B
  • Enterprise Value No Data
  • Avg Volume Fetching Data...
  • P/E Ratio Fetching Data...
  • Dividend Yield Fetching Data...

Industry: Biotechnology

  • ceo: Mr. Timothy Van Hauwermeiren EMBA, M.Sc.
  • IPO Date: July, 10, 2014
  • Country: NL
  • Currency: EUR
  • Headquaters: No Data
  • Employees: 1148

- Revenue from each product or segment:

Product or Segment Value: % - Total Last 3Y:
news-img

- Revenue by Region

Product or Segment Value: % - Total Last 3Y:
news-img
8 New Orders
close
Theme Customizer

Customize your theme

close

Theme variation